President Trump’s latest tariff threat is essentially a bo-b dropped in the middle of Big Pharma.
The idea of a 200% tariff on pharmaceutical imports is a potential earthquake for a sector that’s heavily reliant on sprawling global supply chains to make the dr-gs Americans depend on.
Unlike steel or copper, where the margins aren't as thin, pharmaceutical stocks face a brutal reality check. The new 200% levy on those imports could potentially triple input costs overnight.
https://www.thestreet.com/investing/one-washington-move-could-shake-big-pharma-to-its-core